

# New combined drug regimen for complete cure of pulmonary Tuberculosis in patient with impaired hepatocellular functioning – a case report

---

## **ABSTRACT**

The research gives new therapeutic regimen to Tuberculosis. Despite of the fact being that the current regimen is a burden on liver functioning; most of these are highly hepatotoxic and increases serum alanine aminotransferase (ALT) manifolds. In the backdrop of such a condition this clinical study has been done. Here 4 drugs were selected and TB infection of a middle aged female patient was cured rapidly in one month who had hepatocellular changes. The regimen in this research has also showed significant improvement of liver functions post-therapy. This is about the “*Mumbai Protocol*” of tuberculosis management.

## **KEYWORDS**

Tuberculosis, Mycobacterium Tuberculosis, Internal Medicine, Infection therapy

## **INTRODUCTION**

With improvement in medical infrastructure and advent of new drugs in therapeutics, we have been able to win over many epidemics and endemics as well. But few infectious diseases like tuberculosis, caused by *Mycobacterium tuberculosis* are still a burden over the health of world population. Almost about 23% of the world population is affected by tuberculosis. Tuberculosis may be localized in different organs of the body, be it the neural meninges or genitalia.

But the primary site of infection is the lungs. Currently the recommended drug regimen used to treat Tuberculosis or TB is an intensive therapy with isoniazid, rifampin, pyrazinamide and ethambutol for 2 months and a prolonged phase therapy for 4 months with isoniazid and rifampin (Payam Nahid et al, 2016, p.853-867). The Centers for disease control and prevention (CDC) immensely advocates the same. But it is to be noted here that apart from ethambutol, all the other three drugs used in this regimen i.e. isoniazid, rifampin and pyrazinamide are highly hepatotoxic (Bethesda,2020). Hence, management of patients with impaired liver function becomes almost next to impossible for clinician by using the current drug regimen. Utilizing the same regimen in such condition blindly may lead to severe complications like drug induced fatty liver, liver cirrhosis and fulminant hepatic failure even. This research deals with utilization of a new regimen of combination drugs for successful permanent remission of tuberculosis without causing any harm to liver functioning. The regimen has been proven out to be a huge success as the TB was remitted after first month of therapy only, however the 4+2 months regimen was continued to prevent recurrence. The clinicians involved in this finding are in high hopes that this regimen might be used successfully used to cure tuberculosis in patients with liver pathologies.

## **MATERIALS AND METHODS**

A controlled instrumental observation and administration of the drugs were done in home set-up. Although no necessity for hospitalization was felt, all essential monitoring of the patient was done on a routine basis daily.

## **CASE REPORT**

The experimental therapy and study was conducted with complete agreement of the patient, safeguarding her physical, psychological and emotional well-being.

## **PATIENT INFORMATION**

This is taken in two parts – Anamnesis vitae and anamnesis morbi

## **ANAMNESIS VITAE**

This includes general information past medical history, family history and lifestyle of the patient.

### **General Information**

The patient is a 40 years old female, Indian by nationality. The patient was born on 27<sup>th</sup> March, 1982 in Kolkata, West Bengal, India. Post-partum conditions have been reported to have been normal. There was normal reflex, appearance, cardiac, pulmonary and neurological status; nether there was neither jaundice nor any infection; APGAR – 5/5. She married from the age of 33 years, with normal psychological and sexual functioning but the patient is nulliparous. She works as a professor in a private sector Indian university in Mumbai. No history of drug abuse has been recorded and consumption of alcohol and smoking of cigarette has been denied. The patient has a normal BMI of 21 and no symptoms of metabolic syndrome. In childhood few episodes of acute liver changes have been reported, although it was treated at home family members and hence exact diagnosis is not available.

### **Past Medical History**

The patient has no chronic systemic disorder. No massive life threatening incidence at past has been reported as well. Menarche was at normal age range of 12-13 years (not remembered exactly). Psychiatric well being has been noted as satisfactory. She had an academically sound career and currently is a successful scholar. At the age of 26 years stress induced gastritis was diagnosed which subsequently subsided with proper sleep and use of pantoprazole 40mg and drotaverine 40mg for a small period of time. Recently she was treated for moderate infection COVID19 and salmutarol inhaler was started on diagnosis of asthma.

### **Family history**

The patient's father, mother and younger brother are of Indian nationality and origin. Her father was diagnosed with papillary carcinoma of the thyroid gland and a complete thyroidectomy was performed. Post operation, voice of her father has crackled and toned down due to possible injury to recurrent laryngeal nerve.

He is also a patient of diabetes mellitus type 2 and arterial hypertension stage 1. The patient's mother has no clinical condition as such, apart from diabetes mellitus type 2 and arterial hypertension stage 1. The patient's younger brother is a patient of mild Schizophrenia and is on selective serotonin reuptake inhibitor drugs.

## **ANAMNESIS MORBI**

It includes, present condition, complaints, general observation, systemic observation and clinical observation of the patient.

### **Primary Complaint**

Her main complaint was that of dyspnea, fatigue, persistent cough, loss of appetite and night sweat. She said that breathlessness increases at night and when she climbs stairs or does any physical activity as such.

### **General Observation**

The patient was suffering from breathlessness, there was immense fatigue and the skin was pale. All neurological symptoms like Shchetkin Blumberg sign was negative. No tremor was noticed. Pulse was counted 77 beats/min. There was persistent coughing of non-productive type.

### **Cardiac System**

Borders of heart on percussion were found to be in normal position. The left apex impulse was heard at normal position. The heart sounds were normal on auscultation. The pulse was 77 beats/min.

### **Respiratory system**

Breathing was exacerbated. Thoracic breathing with paroxysm was noticed. Deflections of right and left scapula were equal. On auscultation, wheezing and crackling sounds were heard prominently.

### **Digestive system**

Normal position of stomach in the left hypochondrium, diaphragm was situated without any changes. Slightly increased size of liver was felt on palpation of right hypochondrium and it was slightly painful to palpate as well. Couvier's sign was negative. No pain was felt on palpation along the intestine. Bowel sounds were normal on auscultation.

### **Urinary system**

She urinates up to 6 to 7 times daily. There is no pain in kidney on palpation.

### **Nervous system**

Neurological condition is satisfactory. No neurological symptoms were noted. No change in perception of colour or smell was noted. Psychologically the patient was healthy. No cognitive impairment was reported.

### **INITIAL DIAGNOSTICS AND ASSESSMENT**

Based on the symptoms and previously diagnosed asthma, pulmonary tuberculosis was suspected with histopathological changes of the hepatocytes. Hence a Mantoux test and IGRA were done to assess presence of *Mycobacterium tuberculosis* and a liver function test was carried out to assess the functionality of liver.

The result of Mantoux test is hereby attached below, showing positive tuberculin.

FOR REVIEW

Mobile : \_\_\_\_\_ Employee : \_\_\_\_\_


**IMMUNOLOGY - SEROLOGY**

Test Name	Value	Unit	Normal Value
<b>MONTOUX TEST(A)</b>			
10 T.U. OF TUBERCULIN IS GIVEN INTRADERMALLY, REPORT AFTER 72 HRS :			
<b>POSITIVE</b>			
INDURATION	18X20	MM	
KINDLY NOTE :			
1. MX TEST MAY BE FALSE NEGATIVE WHEN PATIENT			
A. IS ON CIPROBID, ANTI TUBERCULAR DRUGS OR STEROID TREATMENT.			
B. IS IMMUNOCOMPROMISED AS IN HIV, MALIGNANCY.			
2. MX TEST MAY APPEAR STRONGLY POSITIVE			
A. IF TEST IS REPEATED			
B. IN ALLERGIC/IMMUNOSENSITIVE DISORDERS.			

\*\*\* End of the Report \*\*\*





g 1: Imuunology serology report

To confirm the diagnosis and rule out false negative results, an IGRA or interferon gamma releasing assay was performed. The result of IGRA also showed positive for TB antigens. The result has been attached below.



Regd. Office/National Reference Lab: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085  
 Tel: +91-11-30244-100, 3988-5050, Fax: +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com  
 Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065388

A44 - TREHAN CC  
 Opp. Hill View Garden, Trehan, Via-Bhliwadi  
 Alwar, Raj, 301018, Ph-7073886636

Name	: [REDACTED]	Collected	: [REDACTED]	8:11:00AM
Lab No.	: 299825108	Age	: [REDACTED]	Received
		Gender	: Female	Reported
				10:50:24AM
A/c Status	: P	Ref By	: SELF	Report Status
				: Final

Test Name	Results	Units	Bio. Ref. Interval
<b>TB GOLD PLUS, INTERFERON GAMMA RELEASE ASSAY (IGRA), PLASMA (EIA)</b>			
TB1 Antigen tube Minus Nil Tube	1.04	IU/mL	
TB2 Antigen tube Minus Nil Tube	1.81	IU/mL	
Mitogen tube Minus Nil Tube	9.47	IU/mL	
Nil tube	0.02	IU/mL	
Final Result	Positive		

Fig 2: Pathological test report

To assess the extent of hepato-cellular functions a liver function test was done too. Since, on palpation, right hypochondrium was painful. The test results showed increased ALT and globulin with decreased total protein and albumin. The findings were suggestive of suspected mild grade non-alcoholic fatty liver disease (NAFLD).

SARJEEV DIAGNOSTIC CENTRE				
• 1465, Saini Mohalla, Opp. Health Centre, Najafgarh, New Delhi-43. • Vikas Hospital, 1629-H, Thana Road, Najafgarh, New Delhi-43 Ph. : 7836862244				
Lab No	092104250008	UID	11907	
Name	[REDACTED]	W/O	[REDACTED]	
Age / Sex	[REDACTED] FEMALE	Ref. By	[REDACTED]	
Reg Date	[REDACTED]	Reported on	[REDACTED]	
Sr.No.	408			
Test Name	Result	Status	Ref. Range	Unit
<b>BIOCHEMISTRY</b>				
<b>LIVER FUNCTION TEST (LFT)</b>				
Bilirubin ( Total )	0.26		0.0-1.0	mg/dL
Bilirubin (Direct)	0.13			mg/dL
Bilirubin ( Indirect )	0.13			mg/dL
Total Protein	5.7	Low	6.4-8.3	gm/dl
Albumin	2.4	Low	3.50-5.00	gm/dl
Globulin	3.30	High	0.0-3.0	g/dL
A/G Ratio	0.73	Low	1.2-2.0	
SGOT (AST)	31		5-40	U/l
SGPT (ALT)	50	High	0.0-49.0	IU/L
Alk. Phosphatase	58		30.0-120.0	U/L

Fig 3: Diagnostic report

From the patient's condition, it was not suitable to use the usual anti-tuberculosis drug regimen comprising of isoniazid, pyrazinamide, rifampin and ethambutol, because of their hepatotoxicity. Hence, an experimental approach was taken and a new regimen was formulated with drugs which have shown to be having somewhat anti-tuberculosis properties.


### THE EXPERIMENTAL THERAPY

The drugs which were selected are Streptomycin, cycloserine, p-amino salicylic acid and ethambutol. The first 2 months regimen of intensive therapy included all the four drugs. Streptomycin 1g intramuscular injection was given twice a week in a gap of three days, cycloserine 500mg PO was given twice daily, p-amino salicylic acid 4g PO was given once daily by sprinkling on slightly acid food diet and ethambutol 400mg PO was given once daily.





In the continuation phase of 4 months, only cycloserine 500mg PO once daily and ethambutol 400mg PO once daily were used.

## FOLLOW-UP AND OUTCOME

It is a known fact for clinicians that after 2 weeks of intensive therapy phase, the tuberculosis becomes latent in most of the cases but for test report to be negative, at least the first 2 months of therapy has to be completed. But outrageous surprising that in this study test for IGRA was done after 1 month of intensive therapy phase since symptoms were markedly reduced. An IGRA was conducted and the result showed negative for tuberculosis. The patient was unwilling to conduct another Mantoux test and hence it was avoided, neither was any necessity for it felt from clinicians point of view. The IGRA test report after 1 month of intensive phase therapy has been attached below.


Regd. Office/National Reference Lab: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085  
Tel: +91-11-30244-100, 3988-5050, Fax: +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com  
Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065386

**A44 - TREHAN CC**  
Opp. Hill View Garden, Trehan, Via-Bhiwadi  
Alwar, Raj, 301018, Ph-7073888698

Name	██████████	Age	██████████	Gender	Female	Collected	██████████ 8:01:00AM
Lab No.	312450076	Ref By	SELF	Received	Reported	██████████	11:50:54AM
A/c Status	P	Report Status	Final	Reported	██████████	██████████	3:16:00PM

Test Name	Results	Units	Bio. Ref. Interval
<b>TB GOLD PLUS, INTERFERON GAMMA RELEASE ASSAY (IGRA), PLASMA (EIA)</b>			
TB1 Antigen tube Minus Nil Tube	0.08	IU/mL	
TB2 Antigen tube Minus Nil Tube	0.33	IU/mL	
Mitogen tube Minus Nil Tube	9.82	IU/mL	
Nil tube	0.05	IU/mL	
<b>Final Result</b>	<b>NEGATIVE</b>		






Fig 4: The IGRA test report after 1 month of intensive phase therapy

Thus the patient was cured of tuberculosis, no TB antigen were present anymore.

To assess the liver condition post-therapy, a liver function test was conducted again. The LFT test report was highly satisfactory. All parameters were normal;

ALT which was increased in earlier report is now slightly decreased along with rationally slightly increased ALT/AST ratio. The result of LFT has been attached

bel  
ow  
thu  
s.

		Regd. Office/National Reference Lab: Dr. Lal PathLabs Ltd., Block E, Sector-18, Rohini, New Delhi - 110085 Tel: +91-11-30244-100, 3988-5050, Fax: +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065388	
A44 - TREHAN CC Opp. Hill View Garden, Trehan, Via-Bhiwadi Alwar, Raj, 301018, Ph-707388698		   	
Name : ██████████ Lab No. : 312450076 A/c Status : P	Age : ██████████ Ref By : SELF	Gender : Female Collected : ██████████ 8:01:00AM Received : ██████████ 11:50:54AM Reported : ██████████ 3:16:00PM Report Status : Final	
Test Name	Results	Units	Bio. Ref. Interval
<b>LIVER PANEL 1; LFT,SERUM</b>			
AST (SGOT) (RPC without P5P)	19	U/L	13.00 - 35.00
ALT (SGPT) (RPC without P5P)	<10	U/L	10.00 - 49.00
AST:ALT Ratio (Calculated)	2.38		<1.00
GGTP (RPC)	21	U/L	0 - 38
Alkaline Phosphatase (ALP) (RPC-AMP)	83	U/L	30.00 - 120.00
Bilirubin Total (DPD)	0.36	mg/dL	0.30 - 1.20
Bilirubin Direct (DPD)	0.14	mg/dL	<0.3
Bilirubin Indirect (Calculated)	0.22	mg/dL	<1.10
Total Protein (Bimret)	6.40	g/dL	5.70 - 8.20
Albumin (BCG)	3.85	g/dL	3.20 - 4.80
A : G Ratio (Calculated)	1.51		0.90 - 2.00
<b>Note</b> 1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.			

**Fig 5:** The result of LFT

## **RESULT AND DISCUSSION**

The rationale of the drugs selected was such that the drugs should be efficiently anti-TB and at the same time not hepatotoxic or mildly hepatotoxic. Streptomycin is now being used quite frequently to treat multi-drug resistant tuberculosis. It has shown high efficacy in this regard (Waters M et al, 2022). But at the same time it is not hepatotoxic. Although, earlier it was doubted to be but recent findings have suggested that no concrete evidence of streptomycin being hepatotoxic could be identified (Bethesda, 2021). Likewise cycloserine is also utilized in multi-drug resistant tuberculosis with good efficacy. But no strong evidence of hepatotoxicity could have been identified (Bethesda, 2017). P-aminosalicylic acid is now used as a second-line anti-tuberculin drug. But it was frequently and efficaciously used in the 1940s. With passing time this drug was replaced by other newer drugs (Zhang et al, 2019, p.825-829). The drug acts as a pro-drug which generates a toxic dehydrofolate analogue when incorporated in the folate pathway (Zheng et al, 2013, p. 288). In this patient, during the therapy no gastric related anomaly was noticed as a side effect. It might be that the incorporation of the four drugs has some interaction present between them. The primary cause behind replacing it was gastrointestinal irritation. Thus, it was prescribed only for the first 2 months of intensive therapy and was not prescribed for the 4-month prolonged phase therapy. Finally, ethambutol being a drug of regular choice in the treatment of tuberculosis has never shown hepatotoxic properties. Another reason for adding ethambutol to the regimen is to prevent multi-drug resistance (KD Tripathi, 2018, p. 819-820). Thus the candidate was selected for the 4-month prolonged phase therapy as well.

## **CONCLUSION**

*Mycobacterium tuberculosis*, the causative agent of tuberculosis is still a health issue with which strands livelihood of people all around the world. Countries on national level and doctors, nurses and other health worker in ground level have worked hard against this. With emerging multi-resistance against *M. tuberculosis* bacteria, it is immensely important that drug combinations other than the usual regimen are tried. Successful treatment of patients with changed liver function becomes almost impossible with the current regimen as all the drugs in it apart from ethambutol become contraindicated. The authors would like to be named this regimen in memory of the patient as the “*Mumbai protocol*”. Thus, this study is quiet an appreciable breakthrough in clinical science of combination therapy.

## REFERENCES

1. Payam Nahid, Susan E. Dorman, Narges Alipanah, Pennan M. Barry, Jan L. Brozek, Adithya Cattamanchi, Lelia H. Chaisson, Richard E. Chaisson, Charles L. Daley, Malgosia Grzemska, Julie M. Higashi, Christine S. Ho, Philip C. Hopewell, Salmaan A. Keshavjee, Christian Lienhardt, Richard Menzies, Cynthia Merrifield, Masahiro Narita, Rick O'Brien, Charles A. Peloquin, Ann Raftery, Jussi Saukkonen, H. Simon Schaaf, Giovanni Sotgiu, Jeffrey R. Starke, Giovanni Battista Migliori, Andrew Vernon, Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis, *Clinical Infectious Diseases*, Volume 63, Issue 7, 1 October 2016, Pages 853–867, <https://doi.org/10.1093/cid/ciw566>
2. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Ethambutol. [Updated 2020 Dec 24]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548745/>
3. Waters M, Tadi P. Streptomycin. [Updated 2022 Jul 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK555886/>
4. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and

Kidney Diseases; 2012-. Streptomycin. [Updated 2021 Sep 15]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548821/>

5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Cycloserine. [Updated 2017 Nov 3]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK547876/>
6. Zhang, T., Jiang, G., Wen, S., Huo, F., Wang, F., Huang, H., & Pang, Y. (2019). Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of *Mycobacterium tuberculosis*. *Infection and drug resistance*, 12, 825–829. <https://doi.org/10.2147/IDR.S200697>
7. Zheng, J., Rubin, E. J., Bifani, P., Mathys, V., Lim, V., Au, M., Jang, J., Nam, J., Dick, T., Walker, J. R., Pethe, K., & Camacho, L. R. (2013). para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in *Mycobacterium tuberculosis*. *The Journal of biological chemistry*, 288(32), 23447–23456. <https://doi.org/10.1074/jbc.M113.475798>
8. Essentials of Medical pharmacology. KD Tripathi. 8<sup>th</sup> edition; chapter-56, antitubercular drugs; January 2018 - p. 819-820.